Headline News

 

Duvakitug phase 2b maintenance data highlights a clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Posted on February 23, 2026

Novo Nordisk’s Wegovy approved for patients with obesity and clinical study showed people lost about 21% of their body weight on average

Posted on February 23, 2026

Novo Nordisk’s CagriSema highlights a 23% weight loss in REDEFINE 4 trial in patients with obesity

Posted on February 23, 2026

Exdensur now approved for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

Posted on February 23, 2026

Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma

Posted on February 23, 2026

ViiV Healthcare’s Cabenuva for HIV highlights efficacy compared to daily oral therapy for people with adherence challenges

Posted on February 23, 2026

Zepbound is officially the most prescribed weight management medication in 2025

Posted on February 23, 2026

Lilly’s Omvoh highlighted that patients with Crohn’s disease maintained steroid-free remission for three years

Posted on February 23, 2026

Lilly’s Taltz and Zepbound delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight

Posted on February 23, 2026

Uplizna approved for generalised Myasthenia Gravis

Posted on February 17, 2026

Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy

Posted on February 17, 2026

Moderna set to enter into a long term agreement with the Government of Mexico

Posted on February 17, 2026

Moderna receives refusal to file letter for its investigational influenza vaccine, mRNA-1010

Posted on February 17, 2026

Thermo Fisher expands real world data interoperability through collaboration with Datavant

Posted on February 17, 2026

USOPC have officially announced the Team USA athlete recovery program in partnership with Eli Lilly

Posted on February 17, 2026